CicloMed aims to improve life for cancer patients

Bladder cancer takes nearly 200,000 lives a year worldwide – and also burdens survivors with a lifetime of monitoring, surgical procedures and chemotherapy treatments. Current standards of care for bladder cancer are difficult for patients, and recurrences are expensive for healthcare.

CicloMed LLC, a developmental-stage pharmaceutical company with a collaborative team of experts in drug development and cancer treatment, aims to change the narrative.

CicloMed is developing a novel drug candidate known as Fosciclopirox (Ciclopirox Prodrug), one of only a few new agents in decades targeting bladder cancer, potentially in its earlier and later stages (non-muscle invasive and muscle invasive bladder cancers).

Fosciclopirox is being evaluated in Phase I clinical studies. A first-in-human study completed in 2019 characterized the safety, dose tolerance, pharmacokinetics and pharmacodynamics of the compound in advanced cancer patients. A Phase I expansion cohort study is evaluating Fosciclopirox in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) patients. While still in early stages of development, this new agent holds potential to transform treatment of bladder cancer, improving outcomes for patients and reducing burdensome recurrences.

Our paradigm-changing approach to bladder cancer springs from a productive public-private partnership with The University of Kansas Cancer Center. Scientists at KU discovered Ciclopirox Prodrug and demonstrated its potential in preclinical models as an anticancer agent.  Ciclopirox Prodrug for Injection was licensed to CicloMed in 2015. Our team is collaborating with experts across the country to develop this novel drug for the treatment of muscle invasive and non-muscle invasive bladder cancer.

Fosciclopirox is part of an open-label, Phase 1B/2A study to characterize the efficacy, safety, PK, and pharmacodynamics of fosciclopirox administered alone and in combination with cytarabine in patients with relapsed or refractory AML.

CicloMed is a portfolio company of BioNovus Innovations LLC, a unique venture formed to invest in individuals and organizations that are transforming healthcare. BioNovus is charting a new path with the financial investment and commitment to bring novel solutions to reality.